Stock listing

Munich:5LB0 BioVaxys Technology Corp Aktie

German listing (Munich) of BioVaxys Technology Corp · home listing CSE:BIOV

Follow BioVaxys Technology Corp into a list and get an email when it puts out news.

Home listing price · CSE:BIOV

$0.07 CAD 0.00 (0.0%)

Close on Oct 9, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:BIOV

Past 3 months 0.0% · daily closes, Jul 6, 2026 – Oct 9, 2026, adjusted for splits

Day range: $0.07 – $0.07 CADOct 9, 2026

Prices by listing

Listing	Last	Change	Volume	Open	High	Low	Previous close	Price from
CSE:BIOV · Home	$0.07 CAD	0.00 (0.0%)	—	$0.07	$0.07	$0.07	$0.07	Close on Oct 9, 2026
OTC:BVAXF	$0.09 USD	0.00 (0.0%)	10,009	$0.09	$0.09	$0.075	$0.09	Close on Oct 16, 2026

Daily closes

Last 3 months, Jul 9, 2026 – Oct 9, 2026 · CSE:BIOV · CAD, adjusted for splits

Day	Close	%	Open	High	Low
Fri, Oct 9	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Oct 8	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Oct 7	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Oct 6	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Oct 5	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Oct 2	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Oct 1	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 30	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 29	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Sep 28	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 25	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 24	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 23	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 22	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Sep 21	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 18	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 17	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 16	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 15	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Sep 14	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 11	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 10	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 9	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 8	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Sep 4	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Sep 3	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Sep 2	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Sep 1	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 31	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 28	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 27	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 26	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 25	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 24	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 21	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 20	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 19	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 18	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 17	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 14	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 13	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 12	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 11	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Aug 10	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Aug 7	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Aug 6	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Aug 5	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Aug 4	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Jul 31	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Jul 30	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Jul 29	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Jul 28	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Jul 27	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Jul 24	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Jul 23	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Jul 22	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Jul 21	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Jul 20	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Jul 17	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Jul 16	$0.07	0.0%	$0.07	$0.07	$0.07
Wed, Jul 15	$0.07	0.0%	$0.07	$0.07	$0.07
Tue, Jul 14	$0.07	0.0%	$0.07	$0.07	$0.07
Mon, Jul 13	$0.07	0.0%	$0.07	$0.07	$0.07
Fri, Jul 10	$0.07	0.0%	$0.07	$0.07	$0.07
Thu, Jul 9	$0.07	0.0%	$0.07	$0.07	$0.07

Ticker: Munich:5LB0
Asset type: Stock
Sector: Health care
Industry: Biotechnology
Exchange: Munich
Currency: EUR

What changed lately

Latest news release · Sep 8, 2026
BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Latest deck · November 2025
Investor Presentation (November 2025)
Investor deck · 18 slides

Latest news

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Sep 8, 2026

Closed $0.07 (0.0%) on Sep 8, 2026

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

May 1, 2026

BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 27, 2026

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Mar 17, 2026

BioVaxys Announces Application for Management Cease Trade Order

Mar 3, 2026

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Jan 29, 2026

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

Jan 20, 2026

BioVaxys 1Q2026 R&D and Collaborative Activity

Jan 15, 2026

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

Jan 8, 2026

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Dec 17, 2025

All BioVaxys Technology Corp news

Decks

Investor Presentation (November 2025)
Investor deck · 18 slides · November 2025

BioVaxys Technology Corp on 6ix

Sector: Health care
Industry: Biotechnology
News releases: 16 in the last 12 months · 38 in all · newest Sep 8, 2026 · oldest 2023
Decks: 1 deck · latest November 2025

Where BioVaxys Technology Corp is listed

Listing	Exchange	Country	Currency
CSE:BIOV · Home listing	CSE	Canada	CAD
OTC:BVAXF	OTC	United States	USD
Cboe Canada:BIOV	Cboe Canada	Canada	CAD
Lang & Schwarz:A41C58	Lang & Schwarz	Germany	EUR
LS Exchange:A41C58	LS Exchange	Germany	EUR
Frankfurt:5LB0	Frankfurt	Germany	EUR
gettex:5LB0	gettex	Germany	EUR
Munich:5LB0 · This page	Munich	Germany	EUR
Stuttgart:5LB0	Stuttgart	Germany	EUR

Munich:5LB0 BioVaxys Technology Corp Aktie

Prices by listing

Daily closes

What changed lately

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Investor Presentation (November 2025)

Latest news

BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BioVaxys Announces Application for Management Cease Trade Order

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)

BioVaxys 1Q2026 R&D and Collaborative Activity

BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Decks

Investor Presentation (November 2025)

BioVaxys Technology Corp on 6ix

Where BioVaxys Technology Corp is listed